This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-28. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
=== Developmental factors === Various developmental factors may affect rates of obesity. Breastfeeding, for example, may protect against obesity in later life with the duration of breastfeeding inversely associated with the risk of being overweight later on. A child's body growth pattern may influence the tendency to gain weight. Researchers measured the standard deviation (SD [weight and length]) scores in a cohort study of 848 babies. They found that infants who had an SD score above 0.67 had catch up growth (they were less likely to be overweight) compared to infants who had less than a 0.67 SD score (they were more likely to gain weight). Additionally, breastfeeding for less than six months, compared to six months or more, has been shown to result in a higher growth rate and higher BMI at 18, 36, and 72 months of age. A child's weight may be influenced when he/she is only an infant. Researchers also did a cohort study on 19,397 babies from their birth until age seven and discovered that high-weight babies at four months were 1.38 times more likely to be overweight at seven years old compared to normal-weight babies. High-weight babies at the age of one were 1.17 times more likely to be overweight at age seven compared to normal-weight babies.
== Books == The Science of Desire: The Search for the Gay Gene and the Biology of Behavior (Simon and Schuster, 1994) ISBN 0-684-80446-8 Living with Our Genes: Why They Matter More Than You Think with Peter Copeland (Anchor, 1999) ISBN 0-385-48584-0 The God Gene: How Faith Is Hardwired into our Genes (Doubleday, 2004) ISBN 0-385-50058-0
Bottom-up proteomics is a common method to identify proteins and characterize their amino acid sequences and post-translational modifications by proteolytic digestion of proteins prior to analysis by mass spectrometry. BUP techniques can be an alternative to MALDI-TOF MS approaches, as they allow the identification of bacterial strains and the characterization of potential resistance and virulence factors in a single run. The major alternative workflow used in high-throughput proteomics is called top-down proteomics and does not use proteolytic digestion. Essentially, bottom-up proteomics is a relatively simple and reliable means of determining the protein make-up of a given sample of cells, tissues, etc. In bottom-up proteomics, the crude protein extract is enzymatically digested, followed by one or more dimensions of separation of the peptides by liquid chromatography coupled to mass spectrometry, a technique known as shotgun proteomics. By comparing the masses of the proteolytic peptides or their tandem mass spectra with those predicted from a sequence database or annotated peptide spectral in a peptide spectral library, peptides can be identified and multiple peptide identifications assembled into a protein identification.
Sources: en.wikipedia.org
fluid mosaic model The prevailing scientific model of the structure and properties of cell membranes, according to which the typical membrane consists of back-to-back layers of amphipathic membrane lipids (generally phospholipids or glycolipids) interspersed with a dynamic variety of embedded proteins, carbohydrates, and (especially in animal cells) cholesterol, all of which behave as if suspended in a "two-dimensional liquid", constantly moving laterally between the lipids and interacting with each other and with the cytoplasm and the extracellular space. The membrane as a whole thus retains a fluidity and elasticity which allow it to change shape and adapt to the cell's environment.
== Clinical significance == ALT is commonly measured clinically as part of liver function tests and is a component of the AST/ALT ratio. When used in diagnostics, it is almost always measured in international units/liter (IU/L) or μkat. While sources vary on specific reference range values for patients, 0-40 IU/L is the standard reference range for experimental studies.
By the 1930s, Bryant Park was suffering from neglect and was considered disreputable, as the Sixth Avenue elevated literally overshadowed the park. Over a period of 10 years, about 100 separate plans for Bryant Park's renovation were proposed, but never enacted. In an attempt to revitalize the park, the George Washington Bicentennial Planning Committee and Sears filed plans for a replica of Lower Manhattan's Federal Hall in early 1932. During the construction of the replica, part of the park was fenced off. The Dr. Marion Sims and Washington Irving statues were removed; the statues were later found under the Williamsburg Bridge. The replica was opened to the public in May 1932, charging an admission fee for entry. That November, Manhattan parks commissioner Walter R. Herrick formally notified Sears that the replica had to be torn down, because he did not approve of its proposed conversion into a Great Depression relief center. By the next year, the Bicentennial Committee's funds had been exhausted. The replica was torn down in mid-1933. In an attempt to engage unemployed architects, the Architects' Emergency Committee held a competition for the redesign of Bryant Park in 1933. The winning design was submitted by Lusby Simpson, of Queens. However, due to a lack of funding, the winning design was not implemented immediately. In February 1934, under the leadership of newly appointed parks commissioner Robert Moses, work was started on Simpson's plan.
Sources: en.wikipedia.org
1 September Resurrecting the Mammoth, about the revival of the woolly mammoth; there may be 10 million frozen mammoths in northern Siberia, and many around the Kolyma (river); the Condover mammoth of Shropshire, found in 1986, with a model at the Shropshire Hills Discovery Centre; in 1796, the first true picture of a mammoth was drawn by French zoologist Georges Cuvier; Kazufumi Goto wanted to resurrect the mammoth; Andrei Sher of the Russian Academy of Sciences; the Beryozovka mammoth of 1901 in Beryozovka (Kolyma), is one of the best preserved mammoths found; the Kirgilyakh mammoth (Dima), found on 23 June 1977 on the Kirgilyakh Peninsula; zoologist Adrian Lister, and DNA fragments of the mammoth; Australian reproductive biologist Ceinwen Gearon; Dan Fisher; geoscientist Paul Schultz Martin, and the Quaternary extinction event in the Late Pleistocene that led to the disappearance of the Mammoth species, possibly associated with Clovis culture; geoarchaeologist Vance Haynes; Larry Agenbroad; archaeologist Steven Mithen.
Pompilidotoxins (PMTXs) are toxic substances that can only be found in the venom of several solitary wasps. This kind of wasp uses their venom to offensively capture prey and is relatively harmless to humans. This is in stark contrast to social insects that defend themselves and their colonies with their venom. The pompilidotoxin producing wasps are part of the Pompilinae subfamily which consists of fifty known genus groups of which only two groups are known to produce the toxin. Both groups produce different variants. The first notice of a pompilidotoxin variant was made by Konno et.al in 1997 after a survey was conducted of neurotoxins in solitary wasps that inhabit Japan. He purified and synthesised this toxin, now called α-pompilidotoxin from the solitary spider wasp (Anoplius samariensis). The second, closely related variant, β-pompilidotoxin, was found by Konno et.al. a year later in 1998 in another solitary wasp (Batozonellus maculifrons) In this year Konno et.al. also shed concrete light on the structure and function of these toxins. Anoplius samariensis is known to live distributed over the globe with reported cases in east-Asia, east and central Europe, and Russia. It produces the α-PMTX to act upon the nervous system of a stung victim. This way they can paralyse a wide range of spiders that will then be dragged to the wasp's nest that is located in the ground, in a cavity of a plant stem, or made from mud. The spider wasp lays its eggs on paralysed spiders so that the hatching larvae can feed on living prey.
Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It is administered under the tongue, in the cheek, by injection (intravenous or subcutaneous), or as a skin patch or implant. Maximum pain relief generally occurs within an hour and lasts up to 24 hours. In the United States, buprenorphine/naloxone (Suboxone) is usually prescribed to discourage injection misuse. Both formulations are Schedule III controlled substances. Buprenorphine acts as an agonist, partial agonist, or antagonist at different opioid receptors. It relieves opioid withdrawal and reduces the effects of other opioids. Unlike full agonists such as heroin and methadone, it has a ceiling effect for some effects, including respiratory depression, but retains misuse potential. Side effects include respiratory depression, sleepiness, adrenal insufficiency, QT prolongation, low blood pressure, allergic reactions, constipation, and opioid addiction. It may increase seizure risk in susceptible people; opioid withdrawal after discontinuation is generally less severe than with other opioids. Safety during pregnancy is unclear, but use while breastfeeding is probably safe: infants receive approximately 1–2% of the maternal weight-adjusted dose. The compound acts as a partial agonist of the μ-opioid receptor (MOR), exhibiting approximately 48% maximal efficacy in the reported functional assay. Its signaling profile is biased toward G-protein-mediated signaling, with comparatively weak recruitment of β-arrestins.
== History == Carfilzomib is derived from epoxomicin, a natural product that was shown by the laboratory of Craig Crews at Yale University to inhibit the proteasome. The Crews laboratory subsequently invented a more specific derivative of epoxomicin named YU101, which was licensed to Proteolix, Inc. Scientists at Proteolix invented a new, distinct compound that had potential use as a drug in humans, known as carfilzomib. Proteolix advanced carfilzomib to multiple phase I and II clinical trials, including a pivotal phase 2 clinical trial designed to seek accelerated approval. Clinical trials for carfilzomib continue under Onyx Pharmaceuticals, which acquired Proteolix in 2009. In January 2011, the FDA granted carfilzomib fast-track status, allowing Onyx to initiate a rolling submission of its new drug application for carfilzomib. In December 2011, the FDA granted Onyx standard review designation, for its new drug application submission based on the 003-A1 study, an open-label, single-arm phase IIb trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies, including bortezomib and either thalidomide or lenalidomide. Initial approval was based on response rate. Data demonstrating an overall survival benefit was demonstrated in the ENDEAVOR trial and approved by the FDA.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.